Advertisement

No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age

  • Li Li
  • Li Wei
  • Zi-Gang Xu
  • Lin MaEmail author
Original Research Article

Abstract

Background

Concerns have been raised that propranolol treatment of infantile hemangioma (IH) may be associated with increased risks of adverse effects and growth impairment in preterm infants due to their immature development.

Objective

This study aimed to find out whether treatment of IH with propranolol in preterm infants is associated with higher incidences of long-term adverse effects and growth impairment in comparison with term infants.

Methods

The clinical data of 55 preterm infants and 180 term infants with IH treated with oral propranolol for 6 months were retrospectively collected and analyzed.

Results

The preterm and term patients did not differ significantly in terms of the general characteristics and adverse effect incidence (all p > 0.05). Height, weight, and head circumference of the preterm infants at ages 1, 2, and 3 years did not differ significantly from the normal references (all p > 0.05). In the term patients, only 1-year-old female weight and head circumference were significantly higher than the normal references (both p < 0.05).

Conclusion

Treatment of IH with propranolol for 6 months did not increase the risks for adverse effects or growth impairment up to age 3 years in preterm versus term patients in our study.

Notes

Compliance with Ethical Standards

Funding

This study was supported by the Capital Health Research and Development of Special (2016-2-2093); Beijing Municipal Administration of Hospitals Incubating Program (PX2016014); Beijing Children’s Hospital Clinic-Scientific Young Investigator Program (BCHYIPB-2016-02); and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (NO ZYLX201601).

Conflict of interest

Li Li, Li Wei, Zi-Gang Xu, and Lin Ma have no conflicts of interest to declare.

Ethical standards

This study was approved by the Ethics Committee of Beijing Children’s Hospital, Capital Medical University (No. [2015]-Y-021-D). The need for informed consent for this retrospective study was waived by the Ethics Committee of Beijing Children’s Hospital, Capital Medical University.

References

  1. 1.
    Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile hemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170:907–13.CrossRefGoogle Scholar
  2. 2.
    Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25:168–73.CrossRefGoogle Scholar
  3. 3.
    Hoornweg MJ, Smeulders MJ, Ubbink DT, van der Horst CM. The prevalence and risk factors of infantile haemangiomas: a case-control study in the Dutch population. Paediatr Perinat Epidemiol. 2012;26:156–62.CrossRefGoogle Scholar
  4. 4.
    Amir J, Metzker A, Krikler R, Reisner SH. Strawberry hemangioma in preterm infants. Pediatr Dermatol. 1986;3:331–2.CrossRefGoogle Scholar
  5. 5.
    Anderson KR, Schoch JJ, Lohse CM, Hand JL, Davis DM, Tollefson MM. Increasing incidence of infantile hemangiomas (IH) over the past 35 years: correlation with decreasing gestational age at birth and birth weight. J Am Acad Dermatol. 2016;74:120–6.CrossRefGoogle Scholar
  6. 6.
    Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr. 2008;153(712–5):e1.Google Scholar
  7. 7.
    Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics. 2012;130:e314–20.CrossRefGoogle Scholar
  8. 8.
    Léauté-Labrèze C, Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.CrossRefGoogle Scholar
  9. 9.
    Smithson SL, Rademaker M, Adams S, Bade S, Bekhor P, Davidson S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Aust J Dermatol. 2017;58:155–9.CrossRefGoogle Scholar
  10. 10.
    Baselga Torres E, Bernabéu Wittel J, van Esso Arbolave DL, Febrer Bosch MI, Carrasco Sanz Á, de Lucas Laguna R, et al. Spanish consensus on infantile haemangioma [in Spanish]. Pediatr (Barc). 2016;85:256–65.CrossRefGoogle Scholar
  11. 11.
    Bernabeu-Wittel J, Narváez-Moreno B, de la Torre-García JM, Fernández-Pineda I, Domínguez-Cruz JJ, Coserría-Sánchez F, et al. Oral Nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol. Pediatr Dermatol. 2015;32:853–7.CrossRefGoogle Scholar
  12. 12.
    Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128–40.CrossRefGoogle Scholar
  13. 13.
    Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Ciofi D, Atti M, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174:855–65.CrossRefGoogle Scholar
  14. 14.
    Jiang ZF, Shen Y. Zhu Futang practice of pesiatrics. 8th ed. Beijing: People’s Medical Publishing House; 2015.Google Scholar
  15. 15.
    Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013;30:182–91.CrossRefGoogle Scholar
  16. 16.
    Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–46.CrossRefGoogle Scholar
  17. 17.
    Wedgeworth E, Glover M, Irvine AD, Neri I, Baselga E, Clayton TH, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European propranolol in the treatment of complicated haemangiomas (PITCH) Taskforce survey. Br J Dermatol. 2016;174:594–601.CrossRefGoogle Scholar
  18. 18.
    Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbe G, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138:e20160353.CrossRefGoogle Scholar
  19. 19.
    Erbay A, Sarialioglu F, Malbora B, Yildirim SV, Varan B, Tarcan A, et al. Propranolol for infantile hemangiomas: a preliminary report on efficacy and safety in very low birth weight infants. Turk J Pediatr. 2010;52:450–6.Google Scholar
  20. 20.
    Li L, Ma L. Use of propranolol on a nasal hemangioma in an extremely low birthweight premature infant. J Dermatol. 2015;42:1101–2.CrossRefGoogle Scholar
  21. 21.
    Moyakine AV, Kerstjens JM, Spillekom-van Koulil S, van der Vleuten CJ. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. J Am Acad Dermatol. 2016;75(59–63):e1.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Dermatology, National Center for Children’s Health, Beijing Children’s HospitalCapital Medical UniversityBeijingChina

Personalised recommendations